|
Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease
|
16 October 2019 |
|
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
|
02 October 2019 |
|
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
|
05 September 2019 |
|
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
|
16 July 2019 |
|
Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention
|
11 July 2019 |
|
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
|
01 July 2019 |
|
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®
|
06 June 2019 |
|
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
|
03 June 2019 |
|
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
|
22 May 2019 |
|
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
|
14 May 2019 |